Kestra Medical Technologies Ltd. (KMTS) Price & Analysis

Compare

7 Followers

KMTS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$20.00 - $26.15

Previous CloseN/A

VolumeN/A

Average Volume (3M)158.76K

Market Cap

$1.26B

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.41

Next Earnings

Apr 14, 2025

EPS Estimate

-0.6

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.90

Shares Outstanding51,348,656

10 Day Avg. Volume102,531

30 Day Avg. Volume158,760

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$27.67

Price Target Upside13.96% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

---

Kestra Medical Technologies Ltd. News

---

Bulls Say, Bears Say

Bulls Say

Market ExpansionKestra is seeing opportunity to grow the market with ASSURE, capturing market share from the competitor, Zoll.

Product DifferentiationAssure, the WCD developed by KMTS, is more comfortable to wear, has significantly fewer false alarms, and comes in both male and female versions, improving patient compliance.

Sales GrowthKestra's sales growth profile, with a 46% CAGR over the next three years, combined with a continued gross margin inflection, provides a compelling opportunity across the SMID cap MedTech.

Bears Say

CompetitionKMTS's wearable cardioverter defibrillator (WCD) has advantages over its sole competitor, which will enable it to expand its market share from ~5% in FY25 to at least ~16% in FY29.

Conflict Of InterestInvestors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report.

---

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

―

Mutual Funds

0.26% Other Institutional Investors

99.60% Public Companies and

Individual Investors

Detailed Ownership Overview >

KMTS FAQ

What was Kestra Medical Technologies Ltd.’s price range in the past 12 months?

Kestra Medical Technologies Ltd. lowest stock price was $20.00 and its highest was $26.15 in the past 12 months.

What is Kestra Medical Technologies Ltd.’s market cap?

Kestra Medical Technologies Ltd.’s market cap is $1.26B.

When is Kestra Medical Technologies Ltd.’s upcoming earnings report date?

Kestra Medical Technologies Ltd.’s upcoming earnings report date is Apr 14, 2025 which is 35 days ago.

How were Kestra Medical Technologies Ltd.’s earnings last quarter?

Kestra Medical Technologies Ltd. released its earnings results on Apr 14, 2025. The company reported -$1.25 earnings per share for the quarter, missing the consensus estimate of -$0.603 by -$0.647.

Is Kestra Medical Technologies Ltd. overvalued?

According to Wall Street analysts Kestra Medical Technologies Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kestra Medical Technologies Ltd. pay dividends?

Kestra Medical Technologies Ltd. does not currently pay dividends.

What is Kestra Medical Technologies Ltd.’s EPS estimate?

Kestra Medical Technologies Ltd.’s EPS estimate is -0.6.

How many shares outstanding does Kestra Medical Technologies Ltd. have?

Kestra Medical Technologies Ltd. has 51,348,656 shares outstanding.

What happened to Kestra Medical Technologies Ltd.’s price movement after its last earnings report?

Kestra Medical Technologies Ltd. reported an EPS of -$1.25 in its last earnings report, missing expectations of -$0.603. Following the earnings report the stock price went up 1.259%.

Which hedge fund is a major shareholder of Kestra Medical Technologies Ltd.?

Currently, no hedge funds are holding shares in KMTS

---

Kestra Medical Technologies Ltd. Stock Smart Score

Neutral

Analyst Consensus

Strong Buy

Average Price Target:
$27.67 (13.96% Upside)

News Sentiment

Neutral

Bullish news 50%
Bearish news 50%

Top Smart Score Stocks >

Company Description

Kestra Medical Technologies Ltd.

Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform is the ASSURE WCD, a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The company's Cardiac Recovery System platform also includes a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.

---

KMTS Earnings Call

Q3 2025

0:00 / 0:00

---

KMTS Stock 12 Month Forecast

Average Price Target

$27.67

▲(13.96% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","22":"$22","25":"$25","28":"$28","31":"$31"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$27.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,22,25,28,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.96,23.501538461538463,24.043076923076924,24.584615384615386,25.126153846153848,25.66769230769231,26.20923076923077,26.75076923076923,27.292307692307695,27.833846153846153,28.37538461538462,28.916923076923077,29.45846153846154,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.96,23.322307692307692,23.684615384615384,24.04692307692308,24.40923076923077,24.771538461538462,25.133846153846154,25.49615384615385,25.85846153846154,26.220769230769232,26.583076923076923,26.94538461538462,27.30769230769231,{"y":27.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.96,23.04,23.12,23.2,23.28,23.36,23.44,23.52,23.6,23.68,23.76,23.84,23.92,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.99,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.99,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.99,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.99,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.99,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.99,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.99,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.99,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.99,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.99,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.96,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >